Breastfeeding During Ustekinumab Treatment in Inflammatory Bowel Disease Is Low Risk

A prospective study in women with inflammatory bowel disease shows that ustekinumab is transferred into breast milk at very low levels with no meaningful infant exposure or safety concerns. The findings, presented by Christina Lykke Balmer, indicate that breastfeeding during ustekinumab therapy is safe, with normal child development and no increased risk of infections or adverse events.